This study is looking for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent) or is resistant to platinum-based chemotherapy. Researchers are testing two different daily doses of the drug 2X-121 (600 mg or 800 mg) to find the safest and most effective amount. The goal is to see how well 2X-121 works as a single treatment and to understand its effects on the body. This study aims to enroll 40 participants, and the current recruitment status is unclear. You do not need to have specific BRCA1 or HRD biomarkers to participate.

Study design

This interventional study plans to enroll 40 participants to evaluate the optimal dose of 2X-121.

What's involved

You would take 2X-121 capsules daily in 28-day cycles. The study will monitor you for up to approximately 2 years.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed from enrollment up to approximately 2 years to evaluate the optimal dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.